Celldex Therapeutics | CLDX - Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.81B 13.45B 2025-12
Agenus USD 19.81M 293.94M 2025-12
Amgen USD 5.9B 773M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Celldex Therapeutics USD 87.27M 511.09M 2025-12
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Nektar Therapeutics USD 85.09M 109.3M 2025-09
Northwest Biotherapeutics USD -108.65M 8.26M 2025-09
Pfizer USD 12.91B 79.89B 2025-12
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Roche Holding CHF 21.01B 10.84B 2025-12